皇家飞利浦
估值 各估值倍数与自身5年区间的对比
同业对比 Medical Devices
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 皇家飞利浦 (PHG) | 25.16B | 19.95 | 1.96 | 3.85% |
| Abbott Laboratories (ABT) | 181.50B | 33.94 | 3.55 | 2.33% |
| Medtronic (MDT) | 121.20B | 23.34 | 2.41 | 3.01% |
| Stryker Corp (SYK) | 113.02B | 30.53 | 4.71 | 1.18% |
| Boston Scientific (BSX) | 64.33B | 17.97 | 2.58 | 0.00% |
| Edwards Lifesciences (EW) | 49.92B | 50.35 | 4.70 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算25.6%。
合理价值
Koninklijke Philips NV receives a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 25% discount to our quantitative fair value estimate of $32.32 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The firm's profitability increases our estimated fair value. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio of 12.6, which lies in the bottom 30% compared with peers globally. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be undervalued.
The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.3, for example, ranks in the top 40% globally. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. This characteristic further promotes our favorable price/fair value ratio.
经济护城河
The company's wide quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 20 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
作者:Quantitative Equity Report
报价时间 2026-10-16 20:01:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
皇家飞利浦 讨论区 0 条评论